drugset / Trial / NCT00828958

Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients.

NCT00828958

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to examine the discontinuation rate of schizophrenia patients receiving multiple sequential 2 mL injections of long acting injectable risperidone (an atypical antipsychotic medication) when administered into the deltoid muscle once every 2 weeks.

Timeline

Start
2006-02
Primary completion
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 37.5 mg Intramuscular
Subject Risperidone Other / unclassified 50 mg Intramuscular

Indications